Next Article in Journal
Assessment of Comprehensive Patient-Reported Outcomes Before and After CPAP Therapy in Obstructive Sleep Apnea
Previous Article in Journal
Risk Stratification and Optimal Use of Implantable Cardioverter-Defibrillator Therapy in Primary Prevention of Sudden Cardiac Death in Genetic Cardiomyopathies, with Assessment of the Role of Genetic Variants in Guiding Therapeutic Decisions
Previous Article in Special Issue
The Role of mTOR Signaling in Tumor-Induced Alterations to Neuronal Function in Diffusely Infiltrating Glioma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 13
Issue 11
10.3390/biomedicines13112627
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Biomedicines 2025, 13(6), 1319.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Schmitz et al. The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies. Biomedicines 2025, 13, 1319

by
Alexa E. Schmitz
1,
Shirsa Udgata
1,
Katherine A. Johnson
2 and
Dustin A. Deming
1,2,3,*
1
McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin, Madison, WI 53705, USA
2
University of Wisconsin Carbone Cancer Center, Madison, WI 53705, USA
3
Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA
*
Author to whom correspondence should be addressed.
Biomedicines 2025, 13(11), 2627; https://doi.org/10.3390/biomedicines13112627
Submission received: 8 September 2025 / Accepted: 16 September 2025 / Published: 27 October 2025
(This article belongs to the Special Issue mTOR Signaling in Disease and Therapy)
Versions Notes
Correction
The original article cited the following retracted reference: “18. Yan, J.; Yang, S.; Tian, H.; Zhang, Y.; Zhao, H. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer. Cell Death Dis. 2020, 11, 943.”
Replacements have been applied for the following:
18.
Destefanis, R.A.; Schmitz, A.E.; Steimle, A.K.; Payne, S.N.; Sha, G.C.; Olson, A.M.; Cornelio, A.; Lippert, A.E.L.; Kraus, S.G.; Johnson, K.A.; et al. BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer. Mol. Cancer Ther. 2025, OF1–OF14. https://doi.org/10.1158/1535-7163.MCT-24-1096.
19.
Udgata, S.; Stoecker, J.N.; Shen, X.; Pasch, C.A.; Deming, D.A. Co-existent PIK3CA and ARID1A mutations lead to enhanced sensitivity to PI3K inhibition through PUMA induction by FOXO3a and p53/p21. In Proceedings of the American Association for Cancer Research Annual Meeting 2025, Part 1 (Regular Abstracts), Chicago, IL, USA, 25–30 April 2025; AACR: Philadelphia, PA, USA, 2025; p. 371.
With this correction, the order of some references has been adjusted accordingly. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication [1] has also been updated.

Reference

  1. Schmitz, A.E.; Udgata, S.; Johnson, K.A.; Deming, D.A. The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies. Biomedicines 2025, 13, 1319. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Schmitz, A.E.; Udgata, S.; Johnson, K.A.; Deming, D.A. Correction: Schmitz et al. The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies. Biomedicines 2025, 13, 1319. Biomedicines 2025, 13, 2627. https://doi.org/10.3390/biomedicines13112627

AMA Style

Schmitz AE, Udgata S, Johnson KA, Deming DA. Correction: Schmitz et al. The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies. Biomedicines 2025, 13, 1319. Biomedicines. 2025; 13(11):2627. https://doi.org/10.3390/biomedicines13112627

Chicago/Turabian Style

Schmitz, Alexa E., Shirsa Udgata, Katherine A. Johnson, and Dustin A. Deming. 2025. "Correction: Schmitz et al. The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies. Biomedicines 2025, 13, 1319" Biomedicines 13, no. 11: 2627. https://doi.org/10.3390/biomedicines13112627

APA Style

Schmitz, A. E., Udgata, S., Johnson, K. A., & Deming, D. A. (2025). Correction: Schmitz et al. The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies. Biomedicines 2025, 13, 1319. Biomedicines, 13(11), 2627. https://doi.org/10.3390/biomedicines13112627

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop